Thera-SAbDab

GOMILIXIMAB

>   Structural Summary
TherapeuticGomiliximab
TargetFCER2
Heavy ChainEVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv Structure3fzu [Fvs: CD, HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Gomiliximab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 31A 31B 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 101 102 103 104 105 106 107 108 109 110 111 112 113
gomiliximab E V Q L V E S G G G L A K P G G S L R L S C A A S G F R F T F N N Y Y M D W V R Q A P G Q G L E W V S R I S S S G D P T W Y A D S V K G R F T I S R E N A N N T L F L Q M N S L R A E D T A V Y Y C A S L T T G S D S W G Q G V L V T V S S
3fzu E V Q L V E S G G G L A K P G G S L R L S C A A S G F R F T F N N Y Y M D W V R Q A P G Q G L E W V S R I S S S G D P T W Y A D S V K G R F T I S R E N A K N T L F L Q M N S L R A E D T A V Y Y C A S L T T G S D S W G Q G V L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
gomiliximab D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D I R Y Y L N W Y Q Q K P G K A P K L L I Y V A S S L Q S G V P S R F S G S G S G T E F T L T V S S L Q P E D F A T Y Y C L Q V Y S T P R T F G Q G T K V E I K
3fzu D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D I R Y Y L N W Y Q Q K P G K A P K L L I Y V A S S L Q S G V P S R F S G S G S G T E F T L T V S S L Q P E D F A T Y Y C L Q V Y S T P R T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2004
INN Year Recommended2004
Companies InvolvedBiogen Idec
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAllergic asthma, Allergic rhinitis, Chronic lymphocytic leukaemia
NotesLumiliximab and Gomiliximab are the same mAb

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]